Aktie A2QP3D NERVGEN PHARMA CORP.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen NervGen Pharma Corp.

Aktien

A2QP3D

CA64082X2032

NGEN

Verzögert Toronto S.E.
Andere Börsenplätze
 21:59:35 26.06.2024 		% 5 Tage % 1. Jan.
2.84 CAD +13.60% Intraday Chart für NervGen Pharma Corp. +25.11% +5.19%
25.06. NervGen Pharma bringt neuen Medikamentenkandidaten in präklinisches Proof-of-Concept-Stadium MT
05.06. NervGen Pharma Corp. genehmigt die Wahlen zum Vorstand und Prüfungsausschuss CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
NervGen Pharma to Advance New Drug Candidate into Preclinical Proof-of-Concept Stage
NervGen Pharma to Advance NVG-300 into Preclinical Proof-of-Concept Stage
NervGen Pharma to Present at the 2nd Annual Spinal Cord Injury Investor Symposium
NervGen Pharma Grants Stock Options
NervGen Pharma Announces Results of Annual General Meeting of Shareholders
NervGen Pharma Corp. Approves Board and Audit Committee Elections
NervGen Pharma to Present Two Posters at the American Spinal Injury Association 51st Annual Scientific Meeting
NervGen Pharma to Present Two Posters at the American Spinal Injury Association 51st Annual Scientific Meeting
NervGen Pharma Reports Q1 2024 Financial Results and Operational Updates
NervGen Pharma Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024
NervGen Files Management Information Circular and Announces Board of Directors Transition
Nervgen Pharma Corp. Announces That Bill Radvak, Nervgen's Current Chairman and Co-Founder Will Not Stand for Re-Election and Will Transition to A Continuing Role as an Advisor to the Board
NervGen Pharma : Notice of Meeting and Management Proxy Circular
NervGen Engages Russo Partners LLC to Provide Public Relations Services
NervGen Reports FY 2023 Net Loss of $0.38 Per Share, Provides Operations Update
NervGen Pharma Reports 2023 Year-End Financial Results and Operational Updates
NervGen Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023
Non-Opioid Revolution: Beacons of Hope in Opioid Crisis and a $50 Million Spin-Off
NervGen Pharma Closes C$23 Million Bought Deal Financing
NervGen Completes $23 Million Bought Deal Financing
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2QP3D Aktie
  4. Nachrichten NervGen Pharma Corp.
  5. Andere Sprachen